0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Cardiovascular medicine

Buy Now

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents - Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988 (Hardcover, 1989 ed.) Loot Price: R5,309
Discovery Miles 53 090
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents - Proceedings of the...

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents - Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988 (Hardcover, 1989 ed.)

J. Morganroth, E.Neil Moore

Series: Developments in Cardiovascular Medicine, 100

 (sign in to rate)
Loot Price R5,309 Discovery Miles 53 090 | Repayment Terms: R498 pm x 12*

Bookmark and Share

Expected to ship within 18 - 22 working days

The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.

General

Imprint: Springer
Country of origin: Netherlands
Series: Developments in Cardiovascular Medicine, 100
Release date: October 2002
First published: 1989
Editors: J. Morganroth • E.Neil Moore
Dimensions: 234 x 156 x 19mm (L x W x T)
Format: Hardcover
Pages: 298
Edition: 1989 ed.
ISBN-13: 978-0-7923-0294-0
Categories: Books > Medicine > Clinical & internal medicine > Cardiovascular medicine
Promotions
LSN: 0-7923-0294-X
Barcode: 9780792302940

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

You might also like..

Herbal Bioactive-Based Drug Delivery…
Inderbir Singh Bakshi, Rajni Bala, … Paperback R3,967 Discovery Miles 39 670
Membranes in Pulmonary Vascular Disease…
Patrick Belvitch, Steven Dudek Hardcover R4,414 Discovery Miles 44 140
Encyclopedia of Cardiovascular Research…
Douglas B. Sawyer, Ramachandran S. Vasan Hardcover R43,507 Discovery Miles 435 070
Have You Planned Your Heart Attack…
Warrick Bishop Hardcover R1,507 Discovery Miles 15 070
Heart Failure, An Issue of Critical…
Jennifer Kitchens Hardcover R1,687 Discovery Miles 16 870
Stroke Rehabilitation, An Issue of…
John Chae Hardcover R1,684 Discovery Miles 16 840
Plaque Imaging, An Issue of Neuroimaging…
J Kevin DeMarco Hardcover R1,702 Discovery Miles 17 020
Coronary Artery Disease, An Issue of…
David Shavelle Hardcover R1,693 Discovery Miles 16 930
Lipidology, An Issue of Cardiology…
Edward A. Gill Hardcover R1,696 Discovery Miles 16 960
Team-Based Care for Heart Failure, An…
Gregg C. Fonarow Hardcover R1,697 Discovery Miles 16 970
Atrial Fibrillation, An Issue of…
Hakan Oral Hardcover R1,674 Discovery Miles 16 740
Updates in Cardiac MRI, An Issue of…
Karen Ordovas Hardcover R1,670 Discovery Miles 16 700

See more

Partners